Biopharmaceutical giant AstraZeneca has said that full-year earnings are now expected to come in at the lower end of previous guidance.
While the firm reiterated that core earnings per share (EPS) for 2011 will come within the expected range of $7.20 to $7.40 a share (set out in its third quarter results in October), they are now likely to be in the lower half of forecasts.
Nevertheless, the figure is still an improvement on the $6.71 core EPS reported in 2010.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Astra also reaffirmed its revenue, margin and cash deployment guidance for the period 2010 to 2014.
Back in January 2011, the group said that revenue will be in the range of $28-34bn per annum over the period, "as revenue growth from key franchises that retain exclusivity and continued growth in Emerging Markets are pressured by the loss of market exclusivity on a number of products."
BC
-
‘I installed a heat pump in my home – here are five things I’ve learnt’From the size and noise of a heat pump to how much it costs to run one, Ruth Emery reveals what she’s learnt after installing one in her home six months ago
-
3 ways to work out if a stock is good valueThe only thing you can really control in investing is the price you pay for an asset – but how can you tell if you’re getting a good deal when it comes to the price of a stock?
